
|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
- Volume 0
- Issue 0
Generic Threat
Author(s)Kevin Gopal
Epsom, Surrey, United Kingdom—Pharmaceutical companies struggle to be taken seriously when they talk of facing pressures. A quick look at the bottom line often suggests they are overstating their worries. But new evidence shows they are being squeezed by generic competition and falling R&D output.
Advertisement
Articles in this issue
over 24 years ago
Pharmacies: OTC Price Warsover 24 years ago
One Disease at a Timeover 24 years ago
Overview of the Industry: A World of Opportunitiesover 24 years ago
The Power Shiftover 24 years ago
A Giant Stumblesover 24 years ago
Overruled: No More Dual Pricingover 24 years ago
SubmergedNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
2
Could DTC Programs Help Simplify the Drug-Pricing System?
3
Lilly Enters Definitive Agreement Acquiring Aderum Biotechnologies
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5





